Last year, we looked at Phase II clinical trials of MK-0974, an investigational oral calcitonin gene-related pepitide (CGRP) receptor antagonist, a new type of Migraine abortive. That medication has now been named telcagepant, and is showing great promise as a new Migraine abortive. When I spoke with lead researcher, Dr. Tony Ho, last year, he commented "MK-0974 has a novel new mechanism for relief. Nearly 70% get pain relief at two hours. The results are excellent for sustained relief at...
Reporting from Chicago at the American Headache Society's 49th Annual Scientific Meeting...For a couple of years now, we've been watching,... Read more »
Merck & Company's new Migraine drug Telcagepant which was recently hoping to win FDA approval, has been delayed. The small phase... Read more »
The transcript of this podcast is below. If you prefer to listen to it, you can do so easily from the MigraineCast Web site. Welcome to... Read more »
Merck recently announced they are withdrawing their efforts to win FDA approval for their novel Migraine medication Telcagepant. This is... Read more »
Last year, we looked at Phase II clinical trials of MK-0974, an investigational oral calcitonin gene-related pepitide (CGRP) receptor... Read more »
Phase II study data on MK-0974, an investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist showed:MK-0974 significantly... Read more »
Scientists say they may have found a new "target" for future migraine medicines. New research published in the medical journal The Lancet suggest... Read more »
Scientists say a brain discovery may bring new migraine drugs that don't have the side effects of existing treatments onto the market within the next... Read more »
As MigrainuersAs Migrainuers, we're always looking for better abortive medications to stop Migraines and their associated symptoms in their tracks.... Read more »
Source: Medifocus Guidebook on: Migraine Headache
Goals of Treatment of Migraine HeadacheThe goals of treatment for people with migraine headaches include: Reduce the frequency, severity, and... Read more »